Priority FDA Review And Phase III Data Will Transform This Oncology Pure Play

Catalysts

About Celcuity

Celcuity is a clinical stage oncology company focused on developing gedatolisib, a targeted therapy for advanced breast and prostate cancers.

What are the underlying business or industry changes driving this perspective?

• The FDA has accepted the gedatolisib new drug application with priority review under the real time oncology review program, which is used for therapies that may offer substantial improvements. This timing could accelerate the shift from clinical stage to potential commercial revenue generation.
• The PIK3CA wild type cohort of the Phase III VIKTORIA 1 trial reported progression free survival and response metrics that set new benchmarks in HR positive HER2 negative second line breast cancer. If reflected on the label, these data could support premium pricing and uptake that are supportive for revenue and earnings.
• If the PIK3CA mutant cohort of VIKTORIA 1 reports positive results, gedatolisib could be positioned as a single regimen for second line patients regardless of PIK3CA status. This would simplify treatment decisions for oncologists and can expand the addressable market and potential revenue base.
• Management has highlighted that gedatolisib did not induce clinically relevant hypoglycemia and had low discontinuation rates from adverse events. A favorable safety and tolerability profile often supports better treatment adherence and can contribute to more predictable revenue and margin visibility over time.
• The company estimates approximately 37,000 eligible U.S. patients and a second line total addressable market of more than US$5b for gedatolisib, and internal work suggests this opportunity could support up to US$2.5b in annual peak sales. This is meaningful compared with current operating losses and has the potential to materially affect future earnings power.
• Celcuity has largely completed its commercial build out, including sales force and payer engagement, ahead of a potential 2026 launch. If approval is granted, the company is positioned to convert clinical progress into product revenue and to spread fixed commercial costs over a growing revenue base, which can support net margin improvement over time.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more optimistic perspective on Celcuity compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• Celcuity currently has no revenue. The bullish analysts are forecasting revenue to reach $1.3 billion by May 2029.
• As a pre-revenue company, The bullish analysts expect Celcuity to achieve a profit margin of 36.5% in 3 years time.
• The bullish analysts expect earnings to reach $458.9 million (and earnings per share of $6.53) by about May 2029, up from -$177.0 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $129.3 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 26.3x on those 2029 earnings, up from -34.3x today. This future PE is greater than the current PE for the US Biotechs industry at 17.3x.
• The bullish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.23%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Celcuity is still a loss making, pre revenue company with a full year 2025 net loss of US$177 million and non GAAP adjusted net loss of US$150.8 million, so any delay, negative outcome or narrower than expected label from the FDA review of gedatolisib could extend the loss making period and put pressure on future revenue and earnings.
• The investment case is heavily concentrated in a single asset and a narrow set of indications, with commercial build out, higher R&D and G&A spending already under way ahead of approval. Slower than expected physician adoption or payer access for second line HR positive HER2 negative breast cancer could leave the company with a large fixed cost base and weigh on net margins and earnings.
• Management is planning additional Phase III and earlier stage studies in first line breast cancer and metastatic castration resistant prostate cancer, which adds multi year clinical and regulatory risk. Any setbacks, safety findings or weaker than expected data in these longer term programs could limit the addressable market that underpins long run revenue and earnings potential.
• Cash, cash equivalents and short term investments of US$441.5 million are expected to finance operations through 2027, while net cash used in operating activities for 2025 was US$153.3 million. If commercialization ramp or ex US partnering does not progress as planned, Celcuity may need additional capital that could increase the number of shares outstanding and dilute future earnings per share.
• The thesis assumes a large second line total addressable market of more than US$5b and potential peak revenue of up to US$2.5b annually. Competing therapies targeting the PI3K pathway and other mechanisms are already on the market or in development, and changes in treatment standards, safety perceptions or pricing in oncology over time could reduce achievable market share, limiting long term revenue, net margins and earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Celcuity is $165.0, which represents up to two standard deviations above the consensus price target of $134.18. This valuation is based on what can be assumed as the expectations of Celcuity's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $165.0, and the most bearish reporting a price target of just $94.0.
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $1.3 billion, earnings will come to $458.9 million, and it would be trading on a PE ratio of 26.3x, assuming you use a discount rate of 7.2%.
• Given the current share price of $125.65, the analyst price target of $165.0 is 23.8% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.